Herniation World Federation of Neurosurgical Societies Scale Improves Prediction of Outcome in Patients With Poor-Grade Aneurysmal Subarachnoid Hemorrhage.


Journal

Stroke
ISSN: 1524-4628
Titre abrégé: Stroke
Pays: United States
ID NLM: 0235266

Informations de publication

Date de publication:
07 2022
Historique:
pubmed: 24 3 2022
medline: 30 6 2022
entrez: 23 3 2022
Statut: ppublish

Résumé

Favorable outcomes are seen in up to 50% of patients with World Federation of Neurosurgical Societies (WFNS) grade V aneurysmal subarachnoid hemorrhage. Therefore, the usefulness of the current WFNS grading system for identifying the worst scenarios for clinical studies and for making treatment decisions is limited. We previously modified the WFNS scale by requiring positive signs of brain stem dysfunction to assign grade V. This study aimed to validate the new herniation WFNS grading system in an independent prospective cohort. We conducted an international prospective multicentre study in poor-grade aneurysmal subarachnoid hemorrhage patients comparing the WFNS classification with a modified version-the herniation WFNS scale (hWFNS). Here, only patients who showed positive signs of brain stem dysfunction (posturing, anisocoric, or bilateral dilated pupils) were assigned hWFNS grade V. Outcome was assessed by modified Rankin Scale score 6 months after hemorrhage. The primary end point was the difference in specificity of the WFNS and hWFNS grading with respect to poor outcomes (modified Rankin Scale score 4-6). Of the 250 patients included, 237 reached the primary end point. Comparing the WFNS and hWFNS scale after neurological resuscitation, the specificity to predict poor outcome increased from 0.19 (WFNS) to 0.93 (hWFNS) (McNemar, The identification of objective positive signs of brain stem dysfunction significantly improves the specificity and positive predictive value with respect to poor outcome in grade V patients. Therefore, a simple modification-presence of brain stem signs is required for grade V-should be added to the WFNS classification. URL: https://clinicaltrials.gov; Unique identifier: NCT02304328.

Sections du résumé

BACKGROUND
Favorable outcomes are seen in up to 50% of patients with World Federation of Neurosurgical Societies (WFNS) grade V aneurysmal subarachnoid hemorrhage. Therefore, the usefulness of the current WFNS grading system for identifying the worst scenarios for clinical studies and for making treatment decisions is limited. We previously modified the WFNS scale by requiring positive signs of brain stem dysfunction to assign grade V. This study aimed to validate the new herniation WFNS grading system in an independent prospective cohort.
METHODS
We conducted an international prospective multicentre study in poor-grade aneurysmal subarachnoid hemorrhage patients comparing the WFNS classification with a modified version-the herniation WFNS scale (hWFNS). Here, only patients who showed positive signs of brain stem dysfunction (posturing, anisocoric, or bilateral dilated pupils) were assigned hWFNS grade V. Outcome was assessed by modified Rankin Scale score 6 months after hemorrhage. The primary end point was the difference in specificity of the WFNS and hWFNS grading with respect to poor outcomes (modified Rankin Scale score 4-6).
RESULTS
Of the 250 patients included, 237 reached the primary end point. Comparing the WFNS and hWFNS scale after neurological resuscitation, the specificity to predict poor outcome increased from 0.19 (WFNS) to 0.93 (hWFNS) (McNemar,
CONCLUSIONS
The identification of objective positive signs of brain stem dysfunction significantly improves the specificity and positive predictive value with respect to poor outcome in grade V patients. Therefore, a simple modification-presence of brain stem signs is required for grade V-should be added to the WFNS classification.
REGISTRATION
URL: https://clinicaltrials.gov; Unique identifier: NCT02304328.

Identifiants

pubmed: 35317612
doi: 10.1161/STROKEAHA.121.036699
doi:

Banques de données

ClinicalTrials.gov
['NCT02304328']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2346-2351

Auteurs

Andreas Raabe (A)

Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland (A.R., J.G., W.J.Z.).

Jürgen Beck (J)

Department of Neurosurgery, Faculty of Medicine, Medical Center, University of Freiburg, Germany (J.B., R.R., C.S., M.S., D.H.H., O.S., C.F.).

Johannes Goldberg (J)

Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland (A.R., J.G., W.J.Z.).

Werner J Z Graggen (WJ)

Department of Neurosurgery, Inselspital, Bern University Hospital, University of Bern, Switzerland (A.R., J.G., W.J.Z.).

Mattia Branca (M)

CTU Bern, University of Bern, Switzerland (M.B.).

Serge Marbacher (S)

Department of Neurosurgery, Kantonsspital Aarau, Switzerland (S.M., D.D., J.F.).

Donato D'Alonzo (D)

Department of Neurosurgery, Kantonsspital Aarau, Switzerland (S.M., D.D., J.F.).

Javier Fandino (J)

Department of Neurosurgery, Kantonsspital Aarau, Switzerland (S.M., D.D., J.F.).

Martin N Stienen (MN)

Department of Neurosurgery, University Hospital Zürich Switzerland (M.N.S., M.C.N., L.R.).

Marian C Neidert (MC)

Department of Neurosurgery, University Hospital Zürich Switzerland (M.N.S., M.C.N., L.R.).

Jan-Karl Burkhardt (JK)

Department of Neurosurgery, University Hospital Zürich Switzerland, Department of Neurosurgery, Hospital of the University of Pennsylvania, Penn Medicine, Philadelphia (J.-K.B.).

Luca Regli (L)

Department of Neurosurgery, University Hospital Zürich Switzerland (M.N.S., M.C.N., L.R.).

Martin Hlavica (M)

Department of Neurosurgery, Kantonsspital St. Gallen Switzerland (M.H., M.S.).

Martin Seule (M)

Department of Neurosurgery, Kantonsspital St. Gallen Switzerland (M.H., M.S.).

Michel Roethlisberger (M)

Department of Neurosurgery, University Hospital Basel Switzerland (M.R., R.G.).

Raphael Guzman (R)

Department of Neurosurgery, University Hospital Basel Switzerland (M.R., R.G.).

Daniel Walter Zumofen (DW)

Department of Surgery, Neurology, and Radiology, Maimonides Medical Center, SUNY Downstate University, Brooklyn, NY (D.W.Z.).

Rodolfo Maduri (R)

Avaton Surgical Group, Swiss Medical Network, Clinique de Genolier, Switzerland (R.M.).

Roy Thomas Daniel (RT)

Department of Neurosurgery, University Hospital Lausanne Switzerland (R.T.D.).

Amir El Rahal (A)

Department of Neurosurgery, University Hospital Geneva, Switzerland (A.E.R., M.V.C., P.B., K.S.).

Marco V Corniola (MV)

Department of Neurosurgery, University Hospital Geneva, Switzerland (A.E.R., M.V.C., P.B., K.S.).

Philippe Bijlenga (P)

Department of Neurosurgery, University Hospital Geneva, Switzerland (A.E.R., M.V.C., P.B., K.S.).

Karl Schaller (K)

Department of Neurosurgery, University Hospital Geneva, Switzerland (A.E.R., M.V.C., P.B., K.S.).

Roland Rölz (R)

Department of Neurosurgery, Faculty of Medicine, Medical Center, University of Freiburg, Germany (J.B., R.R., C.S., M.S., D.H.H., O.S., C.F.).

Christian Scheiwe (C)

Department of Neurosurgery, Faculty of Medicine, Medical Center, University of Freiburg, Germany (J.B., R.R., C.S., M.S., D.H.H., O.S., C.F.).

Mukesch Shah (M)

Department of Neurosurgery, Faculty of Medicine, Medical Center, University of Freiburg, Germany (J.B., R.R., C.S., M.S., D.H.H., O.S., C.F.).

Dieter Henrik Heiland (DH)

Department of Neurosurgery, Faculty of Medicine, Medical Center, University of Freiburg, Germany (J.B., R.R., C.S., M.S., D.H.H., O.S., C.F.).

Oliver Schnell (O)

Department of Neurosurgery, Faculty of Medicine, Medical Center, University of Freiburg, Germany (J.B., R.R., C.S., M.S., D.H.H., O.S., C.F.).

Christian Fung (C)

Department of Neurosurgery, Faculty of Medicine, Medical Center, University of Freiburg, Germany (J.B., R.R., C.S., M.S., D.H.H., O.S., C.F.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH